Longevity Startups
430 companies tagged Longevity, with their investors and founders.
Vero BioScience develops a blood-based proteomic test that measures organ-specific protein signatures to assess the biological age of individual organs and detect early signs of age-related disease. The company targets individuals seeking predictive health insights and preventive medicine interventions based on technology developed at Stanford.
1 investor
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies in areas such as metabolic and endocrine disorders. This page presents its board of directors.
1 investor
Vitaliti is developing a therapeutic exercise mimetic intended to restore the ability to gain the benefits of exercise for people with cardiopulmonary disease. The company targets patients with debilitating cardiopulmonary conditions.
1 investor
XO Technology builds the XO Companion Ring, a wearable device that automates health assessments and provides real-time insights for caregivers. It is aimed at senior care facilities to monitor the health and wellness of aging individuals.
1 investor
YEARS operates a preventive health clinic in Berlin offering a one-day comprehensive health check combining whole-body MRI, liquid biopsy for early cancer detection, microbiome and bone density testing, ultrasound, and over 230 biomarkers into a physician-reviewed health profile. It targets individuals seeking preventive screening for cardiovascular, neurodegenerative, metabolic, and cancer risks, with tiered programs including annual follow-up and physician guidance.
1 investor
Yosemite is working toward making cancer non-lethal, focusing on cancer research and treatment.
1 investor
Zylem develops therapeutics for cancer, ocular, and cardiovascular disease, along with anti-aging treatments aimed at mitochondrial restoration, based on a portfolio of metabolic redox modulators (MRMs). Its MRMs are tunable mimics of natural molecules modeled on high-density lipoproteins that target SR-B1 to modulate oxidative stress and inflammation, with an initial pipeline focus on targeted oncology.
1 investor
Kolagen Pharma develops and sells pharmaceuticals, medical devices, and research reagents, and manufactures cosmetics, focusing on collagen-based biomaterials for regenerative medicine. Founded by university researchers in science and pharmacology, it is based within Kyoto University's medical research facilities in Japan.
1 investor
Arktus develops regenerative medicine using iPS cell-derived cartilage implants for knee cartilage repair, combining iPS cell research from Kyoto University with cell 3D-printing technology from Saga University. The company aims to provide patient-specific treatment for knee pain and to extend healthy and athletic lifespans.
1 investor
Mirai Speaker (ζ ͺεΌδΌη€Ύγγ©γ€γΉγγΌγ«γΌ) plans, develops, manufactures, and sells age-tech audio products such as the "Mirai Speaker" and "Mirai Speaker Ear," aimed at making longer lifespans more comfortable through technology. The Tokyo-based company focuses on hearing-support devices for older adults.
1 investor
AION Healthspan develops investigational cell-based and molecular therapies aimed at preventing, delaying, and reversing chronic, metabolic, and autoimmune conditions associated with aging. Building on research from the University of Miami's Diabetes Research Institute and Cell Transplant Center, the company works in regenerative medicine to extend healthy lifespan.
0 investors
Alkahest, a subsidiary of Grifols, is a drug discovery company that analyzes the plasma proteome using AI and multiomics to identify biomarkers and develop therapies for age-related and neurodegenerative diseases. Its pipeline targets conditions including wet AMD, Parkinson's disease, and Alzheimer's disease.
0 investors
Ankasa Regenerative Therapeutics develops ART352-L, a protein-based stem cell activation therapy using human Wnt proteins to enhance bone formation and tissue regeneration in reconstructive surgeries. Its lead indication is augmenting autograft in spinal fusion for degenerative disc conditions, with potential expansion to dental/orthopedic implant osseointegration, fracture repair, and joint arthroplasty.
0 investors
AptamiR Therapeutics is a US biotechnology company in pre-clinical development of microRNA-based oligonucleotide therapeutics (antagomirs), including miR-22-3p drug candidates for cardiometabolic disorders such as obesity, diabetes and fatty liver disease (MAFLD/MASH) and candidates for epithelial ovarian cancer. Its approach modulates multiple target genes simultaneously to address complex metabolic diseases and cancer.
0 investors
Arcadia Communities develops and operates senior living communities offering Independent Living, Assisted Living, and Memory Care for seniors. The privately owned company runs communities in Michigan, Kentucky, Florida, and Tennessee in the United States.
0 investors
AscentX Medical develops injectable regenerative therapy using autologous tissue engineering with microspheres to restore soft tissue function, targeting the aging population and patients in clinical settings. The company is also launching cGMP aseptic fill and finish contract manufacturing (CMO) services for the pharmaceutical and medical device industries.
0 investors
Atlee Biotech develops novel treatments for acute disorders. The company focuses on therapeutics aimed at improving health and longevity.
0 investors
BioAegis Therapeutics is a clinical-stage biotech developing therapies for infectious and non-infectious inflammatory diseases based on a recombinant human form of plasma gelsolin (rhu-pGSN), a blood protein that regulates the immune response. Its platform aims to restore depleted gelsolin levels to control inflammation without suppressing immune function.
0 investors
BioRegenx is a health-technology holding company developing and acquiring patented regenerative biotherapeutics, anti-aging nutraceuticals, and AI-based health monitoring tools, including non-invasive microvascular imaging (GlycoCheck), a plant-based supplement (Endocalyx Pro), and contactless vital-sign analysis (DocSun). It sells through direct-to-institution, direct-to-practitioner, and direct-to-consumer models across the health, wellness, and longevity market.
0 investors
Bioxytran is a clinical-stage pharmaceutical company developing carbohydrate-based drug platforms in glycovirology, hypoxia, and degenerative diseases, using galectin inhibitors to block viral replication and oxygen-carrying treatments for conditions such as stroke, wounds, and brain damage. Its therapies target viruses, hypoxic conditions, necrosis, and degenerative diseases.
0 investors
BodyBio is a third-generation family business that develops and manufactures science-backed dietary supplements and vitamins, including phosphatidylcholine (PC), butyrate, and detox products, aimed at cellular health and wellness. Products are made at the company's in-house facility with third-party testing.
0 investors
bQuest is a care coordination platform that connects financial advisors and their clients to vetted aging care and end-of-life specialists, such as home care providers, senior placement agents, aging life care managers, and grief therapists. It offers advisors client-facing tools, referral networks, and educational content to help guide families through caregiving, home transitions, and end-of-life decisions.
0 investors
Cytonics develops A2M-based biologic therapies for osteoarthritis, including its lead candidate CYT-108, a "super A2M" drug in FDA clinical trials that targets enzymes responsible for cartilage degradation. The company aims to create the first disease-modifying therapy for osteoarthritis rather than treating only symptoms.
0 investors
Edenbridge Health develops and operates PACE (Program for All-Inclusive Care for the Elderly) centers that provide comprehensive, community-based medical and social care for frail, low-income older adults. The company runs centers in markets including Baltimore and Washington, D.C., and partners with housing providers to help elders age in place.
0 investors